// App-Quantinova.ai

: Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Nazli Dizman

Principal Investigators

  • Zeynep Busra Zengin

  • Luis A Meza

  • Nishita Tripathi

  • Nicolas Sayegh

  • Daniela V. Castro

  • Elyse H. Chan

  • Kyle O. Lee

  • Sweta R. Prajapati

  • Matthew I. Feng

  • Vivian Loo

  • Makala Pace

  • Shea O'brien

  • Erin B. Bailey

  • Regina Barragan-Carrillo

  • Alex Chehrazi-Raffle

  • Xiaochen Li

  • Neeraj Agarwal

  • Sumanta Monty Pal

Medical Centers

  • Yale University School of Medicine, New Haven, CT

  • City of Hope, Duarte, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Insituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Belisario Domínguez Secc Xvi, Mexico

Locations

  • Mexico

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved